Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000278215 encodes a pseudogene corresponding to the Fc fragment of IgG, low affinity IIa, receptor, also known as FCGR2A (CD32) pseudogene[3]. As a pseudogene, it does not encode a functional protein product. It is not known to play a direct biological role or serve as a therapeutic target[3]. FCGR2C and other closely related genes in the Fc gamma receptor family can show polymorphisms and gene duplications, contributing to immune diversity[2]; however, ENSG00000278215 specifically refers to an inactivated gene sequence, not an active receptor. ENSG00000278215 is classified as a pseudogene and not a true receptor or active molecule[3]. It does not serve as a receptor, enzyme, or any functional therapeutic target. No biological functions, disease roles, interacting drugs, or clinical biomarker associations are attributed specifically to this pseudogene. Any information related to immune functions, therapeutic antibody responses, or disease mechanisms concerns functional FCGR2A, FCGR2C, or related genes—not the ENSG00000278215 pseudogene itself[2][3]. There is no known clinical or research use of this pseudogene as a biomarker or safety concern. ENSG00000278215 is a non-functional pseudogene and does not correspond to a therapeutic or functional biological target[3]. Any functional or disease-relevant information pertains to closely related true genes (such as FCGR2A or FCGR2C), not this pseudogene[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fc fragment of IgG, low affinity IIa, receptor pseudogene.